

WEDNESDAY 25 SEPTEMBER 2024

WS1 MRD in ALL

Workshop organisers: Ester Mejstrikova (Prague, CZ) and Michaela Reiterová (Prague, CZ)

Level: Intermediate/Advanced. Max. 20 places.

MRD in ALL is essential tool in monitoring treatment efficacy. Despite its frequent use in the majority of modern treatment protocols several issues remains unresolved and questionable. In BCP ALL regeneration of hematogones hampers sensitivity and interpretation might be subjective. Targeted treatment anti-19, anti-CD20 and anti-CD22 influences regeneration of normal B cell precursors. Newly defined subsets of BCP ALL namely characterised by DUX4 rearrangement frequently undergo lineage switch towards monocytic lineage and B cell oriented MRD fails in detection of switched blasts. In T ALL we will discuss the role of immunophenotypic heterogeneity in design of T ALL MRD panels. Category of immature T ALLs ("early T cell precursor leukemia") is frequently characterised by germline configuration of TCR genes resulting in unavailability of MRD assessment by molecular techniques and flow cytometry is crucial in this subset. During the workshop we will analyze FCS files of B and T ALL MRD samples.

09:00-09:45	MRD in BCP ALL introduction	Ester Mejstrikova
09:45-10:30	MRD in BCP ALL practical part	Ester Mejstrikova/Michaela Reiterova
10:30-11:00	<i>Coffee break</i>	
11:00-11:45	MRD in T ALL introduction	Michaela Reiterová
11:45-12:30	MRD in T ALL practical part	Michaela Reiterová/Ester Mejstrikova
14:00	Start ESCCA Conference	